2022 the Taihu Lake Bay Life and Health Future Conference Hand Over Beautiful "Transcript"

　　The three-day "2022 the Taihu Lake Bay Life and Health Future Conference" was successfully concluded on August 6. The Guolian Group and its subsidiary Tin Venture Capital fully demonstrated the mission of state-owned enterprises and the advantages of comprehensive financial empowerment in this conference, and contributed an important force to Wuxi's optimization of the bio pharmaceutical industry innovation ecosystem and building a trillion level life and health industry cluster. The theme of this conference is "Beyond, Integration, Health, and Intelligence", with a total of 18 activities, including 1 opening ceremony and main peak meeting, 2 closed door seminars, 5 parallel summit forums, 7 ecosystem conferences, 1 academic conference, and 2 project roadshows. The conference focuses on the forefront of technology, industry dynamics, policy guidance, investment strategies, and other fields, and carries out multidimensional and diversified exchange activities to explore new technologies, new formats, and new models in the life and health industry. Guolian Group, in collaboration with strategic partners such as CICC, Guodiao Fund, and AstraZeneca, jointly held one parallel summit forum and three ecosystem conferences, and recommended multiple biopharmaceutical companies to participate in the project roadshow.

　　At the opening ceremony of the conference on the morning of August 4th, Guolian Group, AstraZeneca, and CICC Capital officially announced their intention to cooperate in a major strategic partnership. The three parties plan to raise a total of RMB 5 billion for the Wuxi Guolian AstraZeneca CICC Medical Fund. The fund will fully leverage the local location advantages and comprehensive financial service capabilities of Guolian Group, while combining the industrial advantages of AstraZeneca and the financial resources of CICC Capital to promote the integration of medical and health resources in Wuxi and across the country, injecting new momentum into the iteration of the health industry and economic development in the Wuxi region. At the same time, Xi Venture Capital and Guodiao Fund jointly signed on-site contracts for three projects, including Zhongsheng Tianxin and (Wuxi) Biotechnology Co., Ltd., Saina Biotechnology (Beijing) Co., Ltd., and Chuangsheng Group Pharmaceutical Co., Ltd. In the future, Wuxi Venture Capital will further deepen the interaction and cooperation with the National Adjustment Fund, jointly help more high-quality biomedical enterprises grow, and strive to promote the "circle of friends" of the National Fund to extend to the beautiful the Taihu Lake Bay, creating a better future for Wuxi's life and health industry. The parallel summit forum on investment and financing jointly organized by China International Capital Corporation (CICC) and Guolian Group was successfully held on the afternoon of August 4th. Guolian Group and China International Capital Corporation (CICC) have been cooperating comprehensively and deeply for many years, with its subsidiary Xicheng Venture Capital as the main investment platform, establishing multiple medical and health special funds to deeply cultivate Wuxi. So far, it has invested in more than ten projects, and has also explored multiple potential enterprises such as Anshun Yuan and Xibeiman Biotechnology in multiple regions of Wuxi. Among the invested enterprises, there are also projects that have achieved IPO, such as Heyu Medical successfully listed on the Hong Kong Stock Exchange in October last year.

　　At a series of conferences and ecosystem meetings held on August 5th, such as Guodiao Fund and AstraZeneca, elements of Guolian and Xichuang Capital were ubiquitous. Through these ecosystem meetings, the "circle of friends" of the League of Nations and the "circle of friends" of Xichuang Capital have been further expanded. The Secretary of the Party Committee and Chairman of the Board of Directors of the League of Nations Group gave a keynote speech at the AstraZeneca China Ecosystem Conference, examining the context of capital empowering industries from the perspective of the League of Nations. From the process of industrial innovation and development in Wuxi, he talked about the practical achievements and exploratory thinking of the League of Nations Group, especially Xichuang Capital, in helping Wuxi's life and health industry cluster and upgrade. In the face of the "window period" of the explosive growth of the global life and health industry, Tin Venture Capital seized the opportunity to accumulate "living water", and successively participated in the establishment and operation of the second phase of the 73.75 billion yuan National Adjustment Fund, the 5 billion yuan the Taihu Lake Lake Growth Fund, the 1.5 billion yuan municipal angel fund, and the 2.2 billion yuan model of CICC AstraZeneca and the 1 billion yuan model of CICC Guokang. Two special industrial funds, focusing on the mid and high-end value chain, deeply cultivated the potential track of innovative drugs, medical devices, diagnostic reagents, special medical formula food, etc., invested nearly 70 life and health industry projects, with a total amount of about 4 billion yuan, and accumulated more than 200 social and financial capital investments and led the acquisition of Italy NMS, the largest tumor research and development institution in Europe The group has adopted a global capitalization strategy to enhance industrial competitiveness and attract "settling in" investors. It has created a "investment bank+investment+industry landing" model, bringing a group of life and health industry headquarters projects and key technologies such as Zhikang Hongyi, Feijileke, Tianxinhe, Jianshi Medical, and Tianguangtai to Wuxi. It has formed a good interaction with industrial clusters such as Xinwu, Mashan, Huishan, and Jiangyin, further connecting the upstream and downstream of the life and health industry chain and achieving internal and external linkage development.

　　In addition, during this conference, Xi Venture Capital also organized a "Industry, Region, and Capital" docking meeting with the United Nations Research and Development Fund, providing a one-on-one communication platform between various districts and sectors of Wuxi and biopharmaceutical enterprises, promoting effective docking and implementation of industry, region, and capital. Xichuang Capital and AstraZeneca have further extended the connotation of the "365 Smart Chain" biopharmaceutical industry chain party building alliance of Guolian Group, established a closer party building and co construction relationship, led by party building to drive business cooperation, and jointly made greater contributions to the development of Wuxi's biopharmaceutical industry.